Clinical trials bureaucracy: unintended consequences of well-intentioned policy
- 1 December 2006
- journal article
- Published by SAGE Publications in Clinical Trials
- Vol. 3 (6), 496-502
- https://doi.org/10.1177/1740774506073173
Abstract
Background As randomized controlled trials have become the ‘gold standard’ for medical research, a complex regulatory structure for the conduct of clinical trials has emerged. However, this structure has not been adequately assessed to ensure that regulations governing human subjects research actually produce the desired effects.Keywords
This publication has 34 references indexed in Scilit:
- Rescuing the NIH before it is too lateJCI Insight, 2006
- Payment for Quality: Guiding Principles and RecommendationsCirculation, 2006
- Reducing the costs of phase III cardiovascular clinical trialsAmerican Heart Journal, 2005
- Janet Woodcock discusses the role of the FDA in improving pharma productivityNature Reviews Drug Discovery, 2004
- Physician remuneration in industry-sponsored clinical trials: the case for standardized clinical trial budgetsCMAJ : Canadian Medical Association Journal, 2004
- Research bureaucracy in the United Kingdom: Seeking a balance: response from the Department of Health and CORECBMJ, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJama-Journal Of The American Medical Association, 1998
- Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trialThe American Journal of Cardiology, 1990
- The FDA's Critique of the Anturane Reinfarction TrialNew England Journal of Medicine, 1980